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Abstract
The treatment with cytomix of 20 patients with chronic viral hepatitis B, C, and mixed B+C, for the duration of three months was favored. 
The improvement of clinical symptoms in patients with HVBC, HVC, and HVBC+HVCC.  The decrease and normalization of liver and spleen 
sizes, and moderate decrease of cytolysis indices values (ALAT, ASAT).  Seroconversion in the AgHBs and anti-Hbs system with the formation 
of anti-HBs (protective antibodies) in one of nine patients with the diagnosis HVBC.  The improvement of immune status indices, which was 
more marked in patients with HVBC and HVBC+HVCC; there were no noted clinical, biochemical or immunological improvements in the 
patients of the control group.
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Лечение цитомиксом больных хроническим вирусным гепатитом В и С  и микст гепатитом В+С 
Лечение  цитомиксом проводилось у 20 больных вирусными гепатитами В и С и микст гепатитами В+С в течении 3-х месяцев. 
Лечение привело к исчезновению клинической симптоматики, нормализации размеров печени и селезенки и снижению активности 
АЛАТ и АСАТ. Произошла сероконверсия в системе НBsAg и анти-HBs с образованием  анти-HBs у одного больного из 9 с хроническим 
вирусным гепатитом В. Улучшение иммунологического статуса было более выражено у больных с хроническим вирусным гепатитом 
В и микст гепатитом В+С, чего не наблюдалось у пациентов контрольной группы.
Ключевые слова:  хронический, вирусный, гепатит В, С, цитомикс.
Introduction
Viral chronic hepatitis B and C represent a worldwide 
public health problem.  Modern treatment is an antiviral one 
with interferon.  Because of multiple counterindicated side 
effects, only 30-40% of the patients may benefit from this 
treatment.  The aim of our study is to show the efficiency of 
treatment with cytomix in chronic viral hepatitis B, C, and 
the mixed B+C.
Material and Methods
Twenty patients were included in the second group.  They 
were administered only cytomix.  The patients consisted of 15 
men and 5 women between the ages of 18 and 59, the middle 
age being 42, with 7 years; 9 among them with the length of 
diagnosis of HVBC ranging between 1 and 18 years; 10 pa-
tients with the length of diagnosis of HVCC ranging between 
2 and 22 years.  One patient was with mixed chronic viral 
hepatitis B+C.  The length of diagnosis of HVBC was 12 years 
and HVCC 11 years.
Patients with HVCC, HVBC, and mixed HVCC+HVBC 
were clinically examined: anamnesis, liver and spleen palpa-
tion and percussion, chest auscultation and percussion and 
heart auscultation, if needed.
Table 1
Clinical Symptomatology Dynamics in Patients Treated with Cytomix at the Start and the End of Treatment
Symptoms
At the Treatment’s Start At the Treatment’s End
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
HVBC
n = 9
HVCC
n = 10
HVBB + HVCC
n = 1
Asthenia 4 4 1 2 - -
Pains in the right hypochondrium 6 6 1 - 2 -
Vertigo - 6 - - - -
Myalgia 4 2 + 2 2 -
Arthralgia 6 6 + - 2 -
Nausea  - 8 - - - -
General weakness - 2 - - - -
Pruritus - - - - - -
Hepatomegalia 9 10 1 4 4 -
Splenomegaly 9 4 - 4 4
Table 2
The Dynamics of Biochemistry Indices in Patients Treated with Cytomix
Biochemistry Indices
At the Treatment’s Start At the Treatment’s End
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
ALAT (increased) 4 8 - 0 0 0
ASAT
(increased) 2 8 - 0 3 0
Bilirubin (increased) 4 6 - 1 2 0
Thymol test (increased) 4 4 - 0 0 0
Prothrombinic Index (decreased) 4 6 - 0 0 0
The Dynamics of Paraclinical  
and Clinical Investigations
Laboratory exams: serological investigations: the reveal 
of AgHBe, anti-HBe, anti-HBs, anti-HVC IgM; biochemistry 
investigations: the values determinationing ALAT, ASAT, 
bilirubin, tymol test, prothrombin; and clinical exam—hemo-
gram were made at the start and end of treatment.
Patients were administered only cytomix
The first month of treatment with cytomix: 10 granules 
twice a day sublingually, in the morning and evening the first 
5 days; the next 21 days: 3 granules twice a day sublingually, in 
the morning.  On Sundays the medicine was not administered.
The second and third month of treatment with cytomix: 
26 days of 3 granules twice a day sublingually, in the morning 
and the evening, one hour before or after meals.
Results and Discussion
Table 1 shows the clinical symptomatology improvements 
in patients treated with cytomix in all three groups.  The liver 
and spleen dimensions had normalized to 50% of patients in the 
study, and had decreased with 2 cm in the other 50% of patients.
Table 2 shows the normalization of ALAT, thymol test and 
prothrombinic indices values, and the improvement of ASAT 
values after the treatment with cytomix.
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Table 3 shows that chronic viral hepatitis B was AgHBe-
negative in patients from the study.  Anti-HBs had formed 
in patients after treatment in significant titres 91,6UI/l. 
So this may be an index of possible antiviral capacity of 
cytomix.
Anti-HBVC IgM had been revealed with the same fre-
quency at the start and at the end of treatment.  So, possible 
antiviral capacities had not been shown.
Table 4 shows a T cell immunosupression in patients with 
the diagnosis HVBC at the start of  treatment—II degree in 
75% and I degree—in 25%, and a B lymphocytosis III degree 
in 50%, I degree—in 25% patients.  An amelioration to the 
return of immune status normal values had been established 
Table 3
The Dynamics of Viral Markers in Patients Treated with Cytomix
Markers
At the Treatment’s Start At the Treatment’s End
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
AgHBe - - - - - -
Anti-Hbe 9 - 1 9 - 1
Anti-HBs - - - 1 - -
Anti-HVC IgM - 10 1 - 9 1
Table 4
The Dynamics of Immunological Indices in Patients Treated with Cytomix at the Treatment’s Start and End
Index Normal Values
At the Start of Treatment At the End of Treatment 
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
HVBC
n = 9
HVCC
n = 10
HVBC + HVCC
n = 1
Leucocytes (109/l) 4.5-8.0 6.325 ± 0.342 5.5 ± 0.63 4.6 6.95  ± 0.464 5.08 ± 0.649 4.4
Lymphocytes (%) 22-38 37 ± 6.096 34 ± 3.209 41 34.75 ± 6.725 298 ± 3.104 45
Lymphocytes (109/l) 1.2-2.4 2.425 ± 0.249 1.916 ± 0.345 1.9 2.325 ± 0.271 1.56 ± 0.302 2,0
Lymphocytes Ta (%) 20-34 20 ± 3.240 13.8 ± 2.905 16 15.5 ± 1.5 18.6 ± 1.363 16
Lymphocytes Ta (109/l) 0.3-0.7 0.525 ± 0.131 0.286 ± 0.081 0.3 0.377 ± 0.078 0.206 ± 0.068 0.32
Lymphocytes Ttot (%) 55-75 33.75 ± 2.286 40.6 ± 3.108 38 45 ± 5.416 42.4 ± 2.712 41
Lymphocytes Ttot (109/l) 0.9-1.5 0.85 ± 0.125 0.822 ± 0.183 0.7 1.092 ± 0.269 0.66 ± 0.143 0.8
Lymphocytes Tterm (%) 0-5 2.5 ± 1.892 1 ± 0.632 4 0 1.8 ± 1.8 0
Lymphocytes Tterm (109/l) 0-0.09 0.057 ± 0.042 0.02 ± 0.013 0.07 0 0.032 ± 0.032 0
Lymphocytes TFR-E-RFC (%) 38-58 22.75 ± 2.428 28 ± 1.760 25 29.5 ± 3.685 26.2 ± 1.827 30
Lymphocytes TFR-E-RFC (109/l) 0.7-1.1 0.57 ± 0.113 0.558 ± 0.121 0.5 0.725 ± 0.16 0.442 ± 0.104 0.6
Lymphocytes TFS (%) 12-28 11 ± 0.912 12.6 ± 1.503 13 15.5 ± 2.872 17.2 ± 2.537 11
Lymphocytes TFS (109/l) 0.23-0.43 0.267 ± 0.032 0.258 ± 0.064 0.25 0.38 ± 0.114 0.33 ± 0.106 0.22
Lymphocytes EAC-RFC (%) 9-18 27 ± 6.916 22 ± 4.062 22 20 ± 4.242 26.4 ± 2.158 17
Lymphocytes EAC-RFC (109/l) 0.18-0.32 0.64 ± 0.162 0.43 ± 0.114 0.42 0.397 ± 0.058 0.412 ± 0.093 0.34
CIC (U.E.) ≤ 60 45.25 ± 11.360 59.2 ± 15.477 90 66 ± 16.643 45.6 ± 18.004 34
LTL 4-7 7.945 ± 1.181 7.67 ± 1.083 6.5 7.35 ± 1.504 8.22 ± 1.075 5.5
T/B 2.0-5.0 1.715 ± 0.418 2.05 ± 0.430 1.7 2.75 ± 0.850 1.55 ± 0.197 2.4
TFR/TFS 2.0-4.0 2.037 ± 0.380 2.28 ± 0.152 1.9 2.075 ± 0.375 1.668 ± 0.303 2.7
at the end of treatment in 75% and a persistence of B lymp-
hocytosis I degree—in 25% patients.
There was a noted T cell immunosupression in patients 
with the dignosis HVCC at the start  of treatment—III 
degree in 40%, which had been persisting after treatment 
in 20%, a B lymphocytosis II degree—in 20% initially, 
but after tretament lymphocytosis II degree—in 40% of 
patients. Probably, it has an immunomodulator effect on 
humoral immunity.
A T cell immunosuppression in II degree and lym-
phocytosis in I degree was observed in patients with the 
HVBC+HVCC, these indices modified after the tretament 
returned to normal values.
Conclusion
The treatment with Cytomix contributed to:
-  A clinical amelioration in patients with HVBC and 
HVCC.
-  The liver and spleen dimensions were normalilsed in 
50% of patients from the study; and yet, 50% had redu-
ced with 2 cm.
-  The normalization of ALAT, thymol test and prothrom-
bin index values.
-  Anti-HBs in significant titres had revealed in 1 patient 
from 9 with the diagnosis HVBC, that suggests the 
presence of cytomix antiviral capacities.
-  The amelioration of immune status with an immunomo-
dulatory action, which were more conclusive in patients 
with HVBC and HVBC+HVCC.
An analysis of examinations in dynamics on the control 
group had not established any clinical, biochemical, or im-
munological amelioration. This confirms the necessity of a 
pathogenic and immunomodulatory treatment.
The study needs to be continued, taking into account 
some biochemistry and immunological contradictory re-
sults for the determination of patient groups and treatment 
duration.
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